Liver transplantation for primary biliary cirrhosis

Clinics in Liver Disease

Volumn 7, Issue 4, 2003, Pages 941-956

  MacQuillan, Gerry C ^a   Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; COLESTYRAMINE; MITOCHONDRION ANTIBODY; NALTREXONE; ONDANSETRON; OPIATE ANTAGONIST; RIFAMPICIN; URSODEOXYCHOLIC ACID;

ALLOGRAFT; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; DIARRHEA; FATIGUE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETHARGY; LIVER FAILURE; LIVER HISTOLOGY; LIVER TOXICITY; LIVER TRANSPLANTATION; NAUSEA; PLASMAPHERESIS; PRIMARY BILIARY CIRRHOSIS; PRURITUS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; TREATMENT INDICATION;

EID: 0141891212     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00099-0     Document Type: Review

References (50)

1. European Liver Transplant Registry. Registry of the European Liver Transplant Association, 1997. Available at www.eltr.org. Accessed July 2003.
2. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001;33(1): 22-7.
3. Christensen E, Altman DG, Neuberger J, De Stavola BL, Tygstrup N, Williams R. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroentorology 1993;105(6):1865-76.
4. Tinmouth J, Tomlinson G, Heathcote EJ, Lilly L. Benefit of transplantation in primary biliary cirrhosis between 1985-1997. Transplantation 2002;73(2):224-7.
5. Jones EA, Bergasa NV. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol 1999;11(6):623-31.
6. Theal J, Toosi M, Girlan L, Huet P, Burak K, Swain M, et al. Ondansetron ameliorates fatigue in patients with primary biliary cirrhosis (PBC). Hepatology 2002;36(4 Pt. 2):296A.
7. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;1(8638):574-6.
8. Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;1(8537):834-6.
9. Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985;26(3):291-4.
10. Schachschal G, Morgera S, Kupferling S, Neumayer HH, Lochs H, Schmidt HH. Emerging indications for MARS dialysis. Liver 2002;22(Suppl 2):63-8.
11. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002;95(8):547-52.
12. Eriksson LS, Soderman C, Ericzon BG, Eleborg L, Wahren J, Hedenstiema G. Normalization of ventilation/perfusion relationships after liver transplantation in patients with decompensated cirrhosis: evidence for a hepatopulmonary syndrome. Hepatology 1990;12(6):1350-7.
13. Kim WR, Wiesner RH, Poterucha JJ, Therneau TM, Benson JT, Krom RA, et al. Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. Liver Transpl 2000;6(4):489-94.
14. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33(2):464-70.
15. Christensen E, Gunson B, Neuberger J. Optimal timing of liver transplantation for patients with primary biliary cirrhosis: use of prognostic modelling. J Hepatol 1999;30(2):285-92.
16. Kilmurry MR, Heathcote EJ, Cauch-Dudek K, O'Rourke K, Bailey RJ, Blendis LM, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996;23(5):1148-53.
17. Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999;29(1):39-43.
18. Mohamed R, Freeman JW, Guest PJ, Davies MK, Neuberger JM. Pulmonary gas exchange abnormalities in liver transplant candidates. Liver Transpl 2002;8(9):802-8.
19. Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 2002;8(4):382-8.
20. Pilatis ND, Jacobs LE, Rerkpattanapipat P, Kotler MN, Owen A, Manzarbeitia C, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl 2000;6(1):85-91.
21. Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001;96:1160-3.
22. Markus BH, Dickson ER, Grambsch PM, Fleming TR, Mazzaferro V, Klintmalm GB, et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320(26):1709-13.
23. Neuberger JM, Gunson BK, Buckels JA, Elias E, McMaster P. Referral of patients with primary biliary cirrhosis for liver transplantation. Gut 1990;31(9):1069-72.
24. Bonsel GJ, Klompmaker IJ, van't Veer F, Habbema JD, Slooff MJ. Use of prognostic models for assessment of value of liver transplantation in primary biliary cirrhosis. Lancet 1990;335(8688): 493-7.
25. Sagmeister M, Mullhaupt B, Kadry Z, Kullak-Ublick GA, Clavien PA, Renner EL. Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation 2002;73(4):616-22.
26. Heathcote EJ, Stone J, Cauch-Dudek K, Poupon R, Chazouilleres O, Lindor KD, et al. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transpl Surg 1999;5(4):269-74.
27. Farges O, Saliba F, Farhamant H, Samuel D, Bismuth A, Reynes M, et al. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology 1996;23(2):240-8.
28. Candinas D, Gunson BK, Nightingale P, Hubscher S, McMaster P, Neuberger JM. Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet 1995;346(8983):1117-21.
29. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol 1998;29(1):143-50.
30. Adams PC, Ghent CN, Grant DR, Wall WJ. Employment after liver transplantation. Hepatology 1995;21(1):140-4.
31. Hunt CM, Tart JS, Dowdy E, Bute BP, Williams DM, Clavien PA. Effect of orthotopic liver transplantation on employment and health status. Liver Transpl Surg 1996;2(2):148-53.
32. Gross CR, Malinchoc M, Kim WR, Evans RW, Wiesner RH, Petz JL, et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999;29(2):356-64.
33. Van Thiel DH, Gavaler JS. Recurrent disease in patients with liver transplantation: when does it occur and how can we be sure? Hepatology 1987;7(1):181-3.
34. Jones EA. Primary biliary cirrhosis and liver transplantation. N Engl J Med 1982;306(1):41-3.
35. Hashimoto E, Shimada M, Noguchi S, Taniai M, Tokushige K, Hayashi N, et al. Disease recurrence after living liver transplantation for primary biliary cirrhosis: a clinical and histological follow-up study. Liver Transpl 2001;7(7):588-95.
36. Balan V, Abu-Elmagd K, Demetris AJ. Autoimmune liver diseases. Recurrence after liver transplantation. Surg Clin North Am 1999;79(1):147-52.
37. Faust TW. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Semin Liver Dis 2000;20(4):481-95.
38. Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 1986;6(6):1279-84.
39. Dubel L, Farges O, Bismuth H, Sebagh M, Homberg JC, Johanet C. Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. J Hepatol 1995;23(6):674-80.
40. Klein R, Huizenga JR, Gips CH, Berg PA. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J Hepatol 1994;20(2):181-9.
41. Gouw AS, Haagsma EB, Manns M, Klompmaker IJ, Slooff MJ, Gerber MA. Is there recurrence of primary biliary cirrhosis after liver transplantation? A clinicopathologic study in long-term survivors. J Hepatol 1994;20(4):500-7.
42. Van de Water J, Ishibashi H, Coppel RL, Gershwin ME. Molecular mimicry and primary biliary cirrhosis: premises not promises. Hepatology 2001;33(4):771-5.
43. Neuberger J, Thomson R. PBC and AMA. What is the connection? Hepatology 1999;29(1):271-6.
44. Balan V, Batts KP, Porayko MK, Krom RA, Ludwig J, Wiesner RH. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993;18(6):1392-8.
45. Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl 2001;7(4):285-91.
46. Dmitrewski J, Hubscher SG, Mayer AD, Neuberger JM. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. J Hepatol 1996;24(3):253-7.
47. Neuberger J, Wallace L, Joplin R, Hubscher S. Hepatic distribution of E2 component of pyruvate dehydrogenase complex after transplantation. Hepatology 1995;22(3):798-801.
48. Van de Water J, Gerson LB, Ferrell LD, Lake JR, Coppel RL, Batts KP, et al. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 1996;24(5):1079-84.
49. Neuberger J. URSO-panacea or placebo? Hepatology 2000;31(4):1027-8.
50. Neuberger J. Recurrent primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000;14(4):669-80.